We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+9.97%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$642M
AUM Growth
+$30M
Cap. Flow
-$8.58M
Cap. Flow %
-1.34%
Top 10 Hldgs %
52.02%
Holding
62
New
16
Increased
10
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$35.8M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.2M
3
KALA icon
KALA BIO
KALA
+$10.4M
4
AMAG
AMAG Pharmaceuticals
AMAG
+$10.1M
5
NUVA
NuVasive, Inc.
NUVA
+$8.93M

Top Sells

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$30.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$21.6M
4
ENDP
Endo International plc
ENDP
+$18.9M
5
ANGO icon
AngioDynamics
ANGO
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$324B
$7.13M 1.11%
+137,183
New +$7.41M
NVLN
27
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.82M 1.06%
1,948,554
– –
SLGL icon
28
Sol-Gel Technologies
SLGL
$268M
$6.67M 1.04%
+64,770
New +$7.25M
VCEL icon
29
Vericel Corp
VCEL
$2.3B
$6.56M 1.02%
658,900
+572,342
+661% +$4.73M
ESPR
30
DELISTED
Esperion Therapeutics
ESPR
$6.28M 0.98%
+86,786
New +$6.37M
AMRN
31
Amarin Corp
AMRN
$284M
$6.26M 0.98%
103,940
+46,418
+81% +$3.45M
PRTK
32
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.21M 0.97%
477,607
+71,400
+18% +$1.06M
TLGT
33
DELISTED
Teligent, Inc
TLGT
$5.68M 0.89%
169,079
-23,463
-12% -$746K
PCRX icon
34
Pacira BioSciences
PCRX
$1.02B
$5.19M 0.81%
+166,500
New +$5.93M
OXFD
35
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.66M 0.73%
+374,233
New +$4.56M
HZNP
36
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.26M 0.66%
300,000
– –
NTUS
37
DELISTED
Natus Medical Inc
NTUS
$3.82M 0.6%
113,526
-90,874
-44% -$2.88M
PGNX
38
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$3.73M 0.58%
+500,000
New +$3.32M
VAR
39
DELISTED
Varian Medical Systems, Inc.
VAR
$3.68M 0.57%
+30,000
New +$3.58M
NVTA
40
DELISTED
Invitae Corporation
NVTA
$3.52M 0.55%
+750,000
New +$5.35M
VCYT icon
41
Veracyte
VCYT
$4.52B
$3.34M 0.52%
600,658
-145,700
-20% -$902K
ADMA icon
42
ADMA Biologics
ADMA
$1.92B
$3.31M 0.52%
720,529
-381,671
-35% -$1.52M
TTPH
43
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.22M 0.5%
52,432
+7,977
+18% +$700K
MDWD icon
44
MediWound
MDWD
$183M
$2.6M 0.41%
71,429
– –
SCYX icon
45
SCYNEXIS
SCYX
$37M
$2.53M 0.39%
+23,574
New +$3.25M
CDTX
46
DELISTED
Cidara Therapeutics
CDTX
$1.5M 0.23%
18,791
-24,079
-56% -$3.29M
IVTY
47
DELISTED
Invuity, Inc
IVTY
$1.15M 0.18%
+298,800
New +$1.36M
CFRX
48
DELISTED
ContraFect Corporation
CFRX
$633K 0.1%
487
-1,053
-68% -$1.3M
TPST icon
49
Tempest Therapeutics
TPST
$14.8M
$442K 0.07%
186
-2
-1% -$6K
SSKN
50
DELISTED
Strata Skin Sciences
SSKN
$238K 0.04%
20,335
– –
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Broadfin Capital held 62 positions worth $642M, up 4.9% from $612M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital's Q1 2018 filing shows 16 new, 10 increased, 19 reduced and 11 closed positions. Its largest new stake was Adamas Pharmaceuticals: 1,135,203 shares worth $27.1M. The largest sale was Ignyta, Inc., an estimated $30.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 92% a quarter earlier.

  • Broadfin Capital's largest Q1 2018 buy was Adamas Pharmaceuticals: 1,135,203 shares worth $27.1M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q1 2018, an estimated $20.2M increase.
  • Broadfin Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $27.9M.
  • Broadfin Capital fully exited Ignyta, Inc. in Q1 2018, selling an estimated $30.7M.
  • Broadfin Capital's ten largest holdings make up 52% of its $642M portfolio in Q1 2018.
  • Broadfin Capital opened 16 new positions and closed 11 in Q1 2018.
  • Broadfin Capital's portfolio value rose 4.9% quarter-over-quarter to $642M.

Based on Broadfin Capital's 13F filing for Q1 2018, filed 14 May 2018.